#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	coref	5-1[27_0]

#Text=Tyrosine kinase inhibitors ( TKIs ) are widely used drugs as a targeted strategy for cancer treatment with the aim of prolonging progression-free survival .
2-1	16-24	Tyrosine	abstract|abstract[3]|abstract[4]	new|new[3]|new[4]	appos|coref|coref	2-5[0_4]|3-2|3-2[12_3]
2-2	25-31	kinase	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-3	32-42	inhibitors	abstract[4]	new[4]	_	_
2-4	43-44	(	_	_	_	_
2-5	45-49	TKIs	abstract	giv	coref	4-6[23_0]
2-6	50-51	)	_	_	_	_
2-7	52-55	are	_	_	_	_
2-8	56-62	widely	substance[6]	new[6]	coref	11-2[72_6]
2-9	63-67	used	substance[6]	new[6]	_	_
2-10	68-73	drugs	substance[6]	new[6]	_	_
2-11	74-76	as	substance[6]	new[6]	_	_
2-12	77-78	a	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-13	79-87	targeted	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-14	88-96	strategy	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-15	97-100	for	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-16	101-107	cancer	substance[6]|abstract[7]|event[8]	new[6]|new[7]|new[8]	coref	4-13[25_8]
2-17	108-117	treatment	substance[6]|abstract[7]|event[8]	new[6]|new[7]|new[8]	_	_
2-18	118-122	with	substance[6]	new[6]	_	_
2-19	123-126	the	substance[6]|abstract[9]	new[6]|new[9]	_	_
2-20	127-130	aim	substance[6]|abstract[9]	new[6]|new[9]	_	_
2-21	131-133	of	substance[6]|abstract[9]	new[6]|new[9]	_	_
2-22	134-144	prolonging	substance[6]|abstract[9]	new[6]|new[9]	_	_
2-23	145-161	progression-free	substance[6]|abstract[9]|event[10]	new[6]|new[9]|new[10]	coref	5-30[39_10]
2-24	162-170	survival	substance[6]|abstract[9]|event[10]	new[6]|new[9]|new[10]	_	_
2-25	171-172	.	_	_	_	_

#Text=Deregulated tyrosine kinase activity of the BCR-ABL oncoprotein is the biochemical hallmark of Philadelphia chromosome-positive ( Ph+ ) hematological malignancies .
3-1	173-184	Deregulated	abstract[13]	new[13]	coref	3-10[16_13]
3-2	185-193	tyrosine	abstract|abstract[12]|abstract[13]	giv|giv[12]|new[13]	coref|coref	11-12[0_12]|12-11
3-3	194-200	kinase	abstract[12]|abstract[13]	giv[12]|new[13]	_	_
3-4	201-209	activity	abstract[13]	new[13]	_	_
3-5	210-212	of	abstract[13]	new[13]	_	_
3-6	213-216	the	abstract[13]|substance[15]	new[13]|new[15]	_	_
3-7	217-224	BCR-ABL	abstract[13]|abstract|substance[15]	new[13]|new|new[15]	coref	4-6
3-8	225-236	oncoprotein	abstract[13]|substance[15]	new[13]|new[15]	_	_
3-9	237-239	is	_	_	_	_
3-10	240-243	the	abstract[16]	giv[16]	_	_
3-11	244-255	biochemical	abstract[16]	giv[16]	_	_
3-12	256-264	hallmark	abstract[16]	giv[16]	_	_
3-13	265-267	of	abstract[16]	giv[16]	_	_
3-14	268-280	Philadelphia	abstract[16]|person|abstract[18]|event[20]	giv[16]|new|new[18]|new[20]	appos|coref	3-17[0_18]|4-15[26_20]
3-15	281-300	chromosome-positive	abstract[16]|abstract[18]|event[20]	giv[16]|new[18]|new[20]	_	_
3-16	301-302	(	abstract[16]|event[20]	giv[16]|new[20]	_	_
3-17	303-306	Ph+	abstract[16]|abstract|event[20]	giv[16]|giv|new[20]	coref	7-3
3-18	307-308	)	abstract[16]|event[20]	giv[16]|new[20]	_	_
3-19	309-322	hematological	abstract[16]|event[20]	giv[16]|new[20]	_	_
3-20	323-335	malignancies	abstract[16]|event[20]	giv[16]|new[20]	_	_
3-21	336-337	.	_	_	_	_

#Text=Currently , several generations of BCR-ABL TKIs are in clinical use for treatment of these malignancies .
4-1	338-347	Currently	_	_	_	_
4-2	348-349	,	_	_	_	_
4-3	350-357	several	abstract[21]	new[21]	_	_
4-4	358-369	generations	abstract[21]	new[21]	_	_
4-5	370-372	of	abstract[21]	new[21]	_	_
4-6	373-380	BCR-ABL	abstract[21]|abstract|abstract[23]	new[21]|giv|giv[23]	coref|coref	5-3[29_23]|23-14
4-7	381-385	TKIs	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
4-8	386-389	are	_	_	_	_
4-9	390-392	in	_	_	_	_
4-10	393-401	clinical	abstract[24]	new[24]	_	_
4-11	402-405	use	abstract[24]	new[24]	_	_
4-12	406-409	for	abstract[24]	new[24]	_	_
4-13	410-419	treatment	abstract[24]|event[25]	new[24]|giv[25]	coref	5-11[32_25]
4-14	420-422	of	abstract[24]|event[25]	new[24]|giv[25]	_	_
4-15	423-428	these	abstract[24]|event[25]|event[26]	new[24]|giv[25]|giv[26]	_	_
4-16	429-441	malignancies	abstract[24]|event[25]|event[26]	new[24]|giv[25]|giv[26]	_	_
4-17	442-443	.	_	_	_	_

#Text=Introduction of the second-generation TKIs , nilotinib and dasatinib as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts , and this provided a possibility for long-term survival in CML .
5-1	444-456	Introduction	abstract[27]	giv[27]	_	_
5-2	457-459	of	abstract[27]	giv[27]	_	_
5-3	460-463	the	abstract[27]|abstract[28]|abstract[29]	giv[27]|new[28]|giv[29]	coref|coref	9-4[0_28]|10-7[61_29]
5-4	464-481	second-generation	abstract[27]|abstract[28]|abstract[29]	giv[27]|new[28]|giv[29]	_	_
5-5	482-486	TKIs	abstract[27]|abstract[28]|abstract[29]	giv[27]|new[28]|giv[29]	_	_
5-6	487-488	,	abstract[27]|abstract[29]	giv[27]|giv[29]	_	_
5-7	489-498	nilotinib	abstract[27]|abstract[29]|substance	giv[27]|giv[29]|new	coref	10-14
5-8	499-502	and	abstract[27]|abstract[29]	giv[27]|giv[29]	_	_
5-9	503-512	dasatinib	abstract[27]|abstract[29]|substance	giv[27]|giv[29]|new	coref	10-21
5-10	513-515	as	abstract[27]	giv[27]	_	_
5-11	516-526	first-line	abstract[27]|event[32]	giv[27]|giv[32]	ana	5-25[0_32]
5-12	527-536	treatment	abstract[27]|event[32]	giv[27]|giv[32]	_	_
5-13	537-545	resulted	_	_	_	_
5-14	546-548	in	_	_	_	_
5-15	549-554	rapid	event[33]	new[33]	_	_
5-16	555-558	and	event[33]	new[33]	_	_
5-17	559-563	deep	event[33]	new[33]	_	_
5-18	564-573	reduction	event[33]	new[33]	_	_
5-19	574-576	of	event[33]	new[33]	_	_
5-20	577-585	BCR/ABL1	event[33]|abstract|abstract[36]	new[33]|new|new[36]	_	_
5-21	586-592	allele	event[33]|object|abstract[36]	new[33]|new|new[36]	_	_
5-22	593-604	transcripts	event[33]|abstract[36]	new[33]|new[36]	_	_
5-23	605-606	,	_	_	_	_
5-24	607-610	and	_	_	_	_
5-25	611-615	this	event	giv	coref	6-16[44_0]
5-26	616-624	provided	_	_	_	_
5-27	625-626	a	abstract[38]	new[38]	_	_
5-28	627-638	possibility	abstract[38]	new[38]	_	_
5-29	639-642	for	abstract[38]	new[38]	_	_
5-30	643-652	long-term	abstract[38]|event[39]	new[38]|giv[39]	_	_
5-31	653-661	survival	abstract[38]|event[39]	new[38]|giv[39]	_	_
5-32	662-664	in	abstract[38]|event[39]	new[38]|giv[39]	_	_
5-33	665-668	CML	abstract[38]|event[39]|abstract	new[38]|giv[39]|new	coref	6-4
5-34	669-670	.	_	_	_	_

#Text=In addition to CML , several other patient populations were identified that undoubtedly benefited from TKI treatment .
6-1	671-673	In	_	_	_	_
6-2	674-682	addition	_	_	_	_
6-3	683-685	to	_	_	_	_
6-4	686-689	CML	abstract	giv	coref	30-32
6-5	690-691	,	_	_	_	_
6-6	692-699	several	person[42]	new[42]	_	_
6-7	700-705	other	person[42]	new[42]	_	_
6-8	706-713	patient	person[42]	new[42]	_	_
6-9	714-725	populations	person[42]	new[42]	_	_
6-10	726-730	were	_	_	_	_
6-11	731-741	identified	_	_	_	_
6-12	742-746	that	_	_	_	_
6-13	747-758	undoubtedly	_	_	_	_
6-14	759-768	benefited	_	_	_	_
6-15	769-773	from	_	_	_	_
6-16	774-777	TKI	abstract|event[44]	new|giv[44]	coref	7-17
6-17	778-787	treatment	event[44]	giv[44]	_	_
6-18	788-789	.	_	_	_	_

#Text=Patients with Ph+ adult acute lymphoblastic leukemia ( ALL ) may also benefit from an alternate TKI therapy .
7-1	790-798	Patients	person[45]	new[45]	coref	8-5[52_45]
7-2	799-803	with	person[45]	new[45]	_	_
7-3	804-807	Ph+	person[45]|abstract|abstract[47]	new[45]|giv|new[47]	appos|coref	7-9[0_47]|8-8
7-4	808-813	adult	person[45]|abstract[47]	new[45]|new[47]	_	_
7-5	814-819	acute	person[45]|abstract[47]	new[45]|new[47]	_	_
7-6	820-833	lymphoblastic	person[45]|abstract[47]	new[45]|new[47]	_	_
7-7	834-842	leukemia	person[45]|abstract[47]	new[45]|new[47]	_	_
7-8	843-844	(	_	_	_	_
7-9	845-848	ALL	abstract	giv	_	_
7-10	849-850	)	_	_	_	_
7-11	851-854	may	_	_	_	_
7-12	855-859	also	_	_	_	_
7-13	860-867	benefit	_	_	_	_
7-14	868-872	from	_	_	_	_
7-15	873-875	an	abstract[50]	new[50]	_	_
7-16	876-885	alternate	abstract[50]	new[50]	_	_
7-17	886-889	TKI	abstract|abstract[50]	giv|new[50]	_	_
7-18	890-897	therapy	abstract[50]	new[50]	_	_
7-19	898-899	.	_	_	_	_

#Text=In the treatment of pediatric patients with Ph+ ALL
8-1	900-902	In	_	_	_	_
8-2	903-906	the	abstract[51]	new[51]	_	_
8-3	907-916	treatment	abstract[51]	new[51]	_	_
8-4	917-919	of	abstract[51]	new[51]	_	_
8-5	920-929	pediatric	abstract[51]|person[52]	new[51]|giv[52]	coref	9-12[0_52]
8-6	930-938	patients	abstract[51]|person[52]	new[51]|giv[52]	_	_
8-7	939-943	with	abstract[51]|person[52]	new[51]|giv[52]	_	_
8-8	944-947	Ph+	abstract[51]|person[52]|abstract	new[51]|giv[52]|giv	_	_
8-9	948-951	ALL	person	new	_	_

#Text=the addition of TKIs to conventional chemotherapy has improved outcomes of patients .
9-1	952-955	the	event[55]	new[55]	_	_
9-2	956-964	addition	event[55]	new[55]	_	_
9-3	965-967	of	event[55]	new[55]	_	_
9-4	968-972	TKIs	event[55]|abstract	new[55]|giv	ana	10-1
9-5	973-975	to	event[55]	new[55]	_	_
9-6	976-988	conventional	event[55]|substance[57]	new[55]|new[57]	_	_
9-7	989-1001	chemotherapy	event[55]|substance[57]	new[55]|new[57]	_	_
9-8	1002-1005	has	_	_	_	_
9-9	1006-1014	improved	_	_	_	_
9-10	1015-1023	outcomes	abstract[58]	new[58]	_	_
9-11	1024-1026	of	abstract[58]	new[58]	_	_
9-12	1027-1035	patients	abstract[58]|person	new[58]|giv	_	_
9-13	1036-1037	.	_	_	_	_

#Text=It has long been known that second-generation TKIs may have side effects as nilotinib can potentiate a prothrombotic state while dasatinib is known to cause platelet dysfunction e.g. impaired collagen-induced platelet adhesion and aggregation .
10-1	1038-1040	It	abstract	giv	coref	23-14[166_0]
10-2	1041-1044	has	_	_	_	_
10-3	1045-1049	long	_	_	_	_
10-4	1050-1054	been	_	_	_	_
10-5	1055-1060	known	_	_	_	_
10-6	1061-1065	that	_	_	_	_
10-7	1066-1083	second-generation	abstract[61]	giv[61]	coref	22-1[0_61]
10-8	1084-1088	TKIs	abstract[61]	giv[61]	_	_
10-9	1089-1092	may	_	_	_	_
10-10	1093-1097	have	_	_	_	_
10-11	1098-1102	side	abstract[62]	new[62]	coref	23-9[164_62]
10-12	1103-1110	effects	abstract[62]	new[62]	_	_
10-13	1111-1113	as	_	_	_	_
10-14	1114-1123	nilotinib	substance	giv	coref	14-1
10-15	1124-1127	can	_	_	_	_
10-16	1128-1138	potentiate	_	_	_	_
10-17	1139-1140	a	abstract[64]	new[64]	_	_
10-18	1141-1154	prothrombotic	abstract[64]	new[64]	_	_
10-19	1155-1160	state	abstract[64]	new[64]	_	_
10-20	1161-1166	while	_	_	_	_
10-21	1167-1176	dasatinib	substance	giv	coref	13-1
10-22	1177-1179	is	_	_	_	_
10-23	1180-1185	known	_	_	_	_
10-24	1186-1188	to	_	_	_	_
10-25	1189-1194	cause	_	_	_	_
10-26	1195-1203	platelet	object|abstract[67]	new|new[67]	coref|appos	10-31|10-28[69_67]
10-27	1204-1215	dysfunction	abstract[67]	new[67]	_	_
10-28	1216-1220	e.g.	abstract[69]|abstract[70]	giv[69]|giv[70]	appos|appos	10-28[70_69]|10-34[0_70]
10-29	1221-1229	impaired	abstract[69]|abstract[70]	giv[69]|giv[70]	_	_
10-30	1230-1246	collagen-induced	abstract[69]|abstract[70]	giv[69]|giv[70]	_	_
10-31	1247-1255	platelet	object|abstract[69]|abstract[70]	giv|giv[69]|giv[70]	coref	15-14
10-32	1256-1264	adhesion	abstract[69]|abstract[70]	giv[69]|giv[70]	_	_
10-33	1265-1268	and	abstract[70]	giv[70]	_	_
10-34	1269-1280	aggregation	abstract[70]|abstract	giv[70]|giv	_	_
10-35	1281-1282	.	_	_	_	_

#Text=Although both drugs bind to the ATP binding site of the kinase domain of the BCR/ABL protein
11-1	1283-1291	Although	_	_	_	_
11-2	1292-1296	both	substance[72]	giv[72]	ana	12-1[0_72]
11-3	1297-1302	drugs	substance[72]	giv[72]	_	_
11-4	1303-1307	bind	event	new	none|none	11-4[0_197]|24-34
11-5	1308-1310	to	_	_	_	_
11-6	1311-1314	the	place[74]	new[74]	_	_
11-7	1315-1318	ATP	abstract|place[74]	new|new[74]	_	_
11-8	1319-1326	binding	place[74]	new[74]	_	_
11-9	1327-1331	site	place[74]	new[74]	_	_
11-10	1332-1334	of	place[74]	new[74]	_	_
11-11	1335-1338	the	place[74]|abstract[76]	new[74]|new[76]	_	_
11-12	1339-1345	kinase	place[74]|abstract|abstract[76]	new[74]|giv|new[76]	coref	24-20[179_0]
11-13	1346-1352	domain	place[74]|abstract[76]	new[74]|new[76]	_	_
11-14	1353-1355	of	place[74]|abstract[76]	new[74]|new[76]	_	_
11-15	1356-1359	the	place[74]|abstract[76]|substance[78]	new[74]|new[76]|new[78]	_	_
11-16	1360-1367	BCR/ABL	place[74]|abstract[76]|organization|substance[78]	new[74]|new[76]|new|new[78]	_	_
11-17	1368-1375	protein	place[74]|abstract[76]|substance[78]	new[74]|new[76]|new[78]	_	_

#Text=they have different off target inhibitory effect on several other tyrosine kinases .
12-1	1376-1380	they	substance	giv	_	_
12-2	1381-1385	have	_	_	_	_
12-3	1386-1395	different	abstract[81]	new[81]	coref	16-6[115_81]
12-4	1396-1399	off	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-5	1400-1406	target	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-6	1407-1417	inhibitory	abstract[81]	new[81]	_	_
12-7	1418-1424	effect	abstract[81]	new[81]	_	_
12-8	1425-1427	on	abstract[81]	new[81]	_	_
12-9	1428-1435	several	abstract[81]|abstract[83]	new[81]|new[83]	coref	14-14[100_83]
12-10	1436-1441	other	abstract[81]|abstract[83]	new[81]|new[83]	_	_
12-11	1442-1450	tyrosine	abstract[81]|abstract|abstract[83]	new[81]|giv|new[83]	coref	14-15
12-12	1451-1458	kinases	abstract[81]|abstract[83]	new[81]|new[83]	_	_
12-13	1459-1460	.	_	_	_	_

#Text=Dasatinib is a potent multikinase inhibitor , including c-KIT , EPHA2 , platelet-derived growth factor receptor-β , and SFKs .
13-1	1461-1470	Dasatinib	substance	giv	coref	13-3[86_0]
13-2	1471-1473	is	_	_	_	_
13-3	1474-1475	a	substance[86]	giv[86]	coref	15-9[0_86]
13-4	1476-1482	potent	substance[86]	giv[86]	_	_
13-5	1483-1494	multikinase	abstract|substance[86]	new|giv[86]	coref	22-6
13-6	1495-1504	inhibitor	substance[86]	giv[86]	_	_
13-7	1505-1506	,	substance[86]	giv[86]	_	_
13-8	1507-1516	including	substance[86]	giv[86]	_	_
13-9	1517-1522	c-KIT	substance[86]|substance	giv[86]|new	_	_
13-10	1523-1524	,	substance[86]	giv[86]	_	_
13-11	1525-1530	EPHA2	substance[86]|abstract	giv[86]|new	_	_
13-12	1531-1532	,	substance[86]	giv[86]	_	_
13-13	1533-1549	platelet-derived	substance[86]|abstract|abstract[91]|abstract[92]	giv[86]|new|new[91]|new[92]	_	_
13-14	1550-1556	growth	substance[86]|abstract|abstract[91]|abstract[92]	giv[86]|new|new[91]|new[92]	_	_
13-15	1557-1563	factor	substance[86]|abstract[91]|abstract[92]	giv[86]|new[91]|new[92]	_	_
13-16	1564-1574	receptor-β	substance[86]|abstract[92]	giv[86]|new[92]	_	_
13-17	1575-1576	,	substance[86]	giv[86]	_	_
13-18	1577-1580	and	substance[86]	giv[86]	_	_
13-19	1581-1585	SFKs	substance[86]|abstract	giv[86]|new	coref	14-32
13-20	1586-1587	.	_	_	_	_

#Text=Nilotinib is also a second generation TKI with a broad inhibitory spectrum of various tyrosine kinases ( PDGFR , c-KIT , ARG , EPHB4 ) , but it does not inhibit SFKs .
14-1	1588-1597	Nilotinib	substance	giv	coref	14-4[96_0]
14-2	1598-1600	is	_	_	_	_
14-3	1601-1605	also	_	_	_	_
14-4	1606-1607	a	substance[96]	giv[96]	coref	16-4[0_96]
14-5	1608-1614	second	substance[96]	giv[96]	_	_
14-6	1615-1625	generation	abstract|substance[96]	new|giv[96]	coref	27-15[201_0]
14-7	1626-1629	TKI	substance[96]	giv[96]	_	_
14-8	1630-1634	with	substance[96]	giv[96]	_	_
14-9	1635-1636	a	substance[96]|abstract[98]	giv[96]|new[98]	ana	14-28[0_98]
14-10	1637-1642	broad	substance[96]|abstract[98]	giv[96]|new[98]	_	_
14-11	1643-1653	inhibitory	substance[96]|abstract|abstract[98]	giv[96]|new|new[98]	coref	22-7
14-12	1654-1662	spectrum	substance[96]|abstract[98]	giv[96]|new[98]	_	_
14-13	1663-1665	of	substance[96]|abstract[98]	giv[96]|new[98]	_	_
14-14	1666-1673	various	substance[96]|abstract[98]|abstract[100]	giv[96]|new[98]|giv[100]	appos	14-18[0_100]
14-15	1674-1682	tyrosine	substance[96]|abstract[98]|abstract|abstract[100]	giv[96]|new[98]|giv|giv[100]	_	_
14-16	1683-1690	kinases	substance[96]|abstract[98]|abstract[100]	giv[96]|new[98]|giv[100]	_	_
14-17	1691-1692	(	_	_	_	_
14-18	1693-1698	PDGFR	abstract|abstract[102]	giv|giv[102]	appos|appos	14-18[102_0]|14-20[0_102]
14-19	1699-1700	,	abstract[102]	giv[102]	_	_
14-20	1701-1706	c-KIT	abstract[102]|abstract	giv[102]|giv	appos	14-22
14-21	1707-1708	,	abstract[102]	giv[102]	_	_
14-22	1709-1712	ARG	abstract[102]|abstract	giv[102]|giv	appos	14-24
14-23	1713-1714	,	abstract[102]	giv[102]	_	_
14-24	1715-1720	EPHB4	abstract[102]|abstract	giv[102]|giv	coref	18-1[126_0]
14-25	1721-1722	)	_	_	_	_
14-26	1723-1724	,	_	_	_	_
14-27	1725-1728	but	_	_	_	_
14-28	1729-1731	it	abstract	giv	_	_
14-29	1732-1736	does	_	_	_	_
14-30	1737-1740	not	_	_	_	_
14-31	1741-1748	inhibit	_	_	_	_
14-32	1749-1753	SFKs	abstract	giv	_	_
14-33	1754-1755	.	_	_	_	_

#Text=Previous in vitro and ex vivo studies with dasatinib have demonstrated a faulty platelet aggregation .
15-1	1756-1764	Previous	abstract[110]	new[110]	_	_
15-2	1765-1767	in	abstract[110]	new[110]	_	_
15-3	1768-1773	vitro	abstract|abstract[110]	new|new[110]	coref	30-9
15-4	1774-1777	and	abstract[110]	new[110]	_	_
15-5	1778-1780	ex	abstract[109]|abstract[110]	new[109]|new[110]	_	_
15-6	1781-1785	vivo	abstract[109]|abstract[110]	new[109]|new[110]	_	_
15-7	1786-1793	studies	abstract[110]	new[110]	_	_
15-8	1794-1798	with	abstract[110]	new[110]	_	_
15-9	1799-1808	dasatinib	abstract[110]|substance	new[110]|giv	coref	29-6
15-10	1809-1813	have	_	_	_	_
15-11	1814-1826	demonstrated	_	_	_	_
15-12	1827-1828	a	abstract[113]	new[113]	coref	16-9[117_113]
15-13	1829-1835	faulty	abstract[113]	new[113]	_	_
15-14	1836-1844	platelet	object|abstract[113]	giv|new[113]	coref	16-9
15-15	1845-1856	aggregation	abstract[113]	new[113]	_	_
15-16	1857-1858	.	_	_	_	_

#Text=On the contrary nilotinib has no effect on platelet aggregation , at all .
16-1	1859-1861	On	_	_	_	_
16-2	1862-1865	the	_	_	_	_
16-3	1866-1874	contrary	_	_	_	_
16-4	1875-1884	nilotinib	substance	giv	coref	17-5
16-5	1885-1888	has	_	_	_	_
16-6	1889-1891	no	abstract[115]	giv[115]	coref	22-3[160_115]
16-7	1892-1898	effect	abstract[115]	giv[115]	_	_
16-8	1899-1901	on	abstract[115]	giv[115]	_	_
16-9	1902-1910	platelet	abstract[115]|object|abstract[117]	giv[115]|giv|giv[117]	ana|coref	16-13[0_117]|18-11
16-10	1911-1922	aggregation	abstract[115]|abstract[117]	giv[115]|giv[117]	_	_
16-11	1923-1924	,	_	_	_	_
16-12	1925-1927	at	_	_	_	_
16-13	1928-1931	all	abstract	giv	coref	25-16[188_0]
16-14	1932-1933	.	_	_	_	_

#Text=Therefore , we used nilotinib as a negative control in our experiments .
17-1	1934-1943	Therefore	_	_	_	_
17-2	1944-1945	,	_	_	_	_
17-3	1946-1948	we	person	acc	ana	17-11
17-4	1949-1953	used	_	_	_	_
17-5	1954-1963	nilotinib	substance	giv	coref	24-31
17-6	1964-1966	as	_	_	_	_
17-7	1967-1968	a	abstract[121]	new[121]	_	_
17-8	1969-1977	negative	abstract[121]	new[121]	_	_
17-9	1978-1985	control	abstract[121]	new[121]	_	_
17-10	1986-1988	in	_	_	_	_
17-11	1989-1992	our	person|event[123]	giv|new[123]	ana	29-1
17-12	1993-2004	experiments	event[123]	new[123]	_	_
17-13	2005-2006	.	_	_	_	_

#Text=Sarcoma family kinases ( SFKs ) are critical regulators of platelet signaling and activation .
18-1	2007-2014	Sarcoma	abstract|person[125]|abstract[126]	new|new[125]|giv[126]	appos	18-5[0_126]
18-2	2015-2021	family	person[125]|abstract[126]	new[125]|giv[126]	_	_
18-3	2022-2029	kinases	abstract[126]	giv[126]	_	_
18-4	2030-2031	(	_	_	_	_
18-5	2032-2036	SFKs	abstract	giv	coref	18-8[128_0]
18-6	2037-2038	)	_	_	_	_
18-7	2039-2042	are	_	_	_	_
18-8	2043-2051	critical	abstract[128]	giv[128]	coref	19-1[132_128]
18-9	2052-2062	regulators	abstract[128]	giv[128]	_	_
18-10	2063-2065	of	abstract[128]	giv[128]	_	_
18-11	2066-2074	platelet	abstract[128]|object|abstract[130]	giv[128]|giv|new[130]	coref|coref	20-8|21-28[153_130]
18-12	2075-2084	signaling	abstract[128]|abstract[130]	giv[128]|new[130]	_	_
18-13	2085-2088	and	abstract[128]	giv[128]	_	_
18-14	2089-2099	activation	abstract[128]|event	giv[128]|new	coref	20-3
18-15	2100-2101	.	_	_	_	_

#Text=These kinases play a central role in mediating rapid response of platelets to vascular injury .
19-1	2102-2107	These	abstract[132]	giv[132]	coref	21-10[144_132]
19-2	2108-2115	kinases	abstract[132]	giv[132]	_	_
19-3	2116-2120	play	_	_	_	_
19-4	2121-2122	a	abstract[133]	new[133]	_	_
19-5	2123-2130	central	abstract[133]	new[133]	_	_
19-6	2131-2135	role	abstract[133]	new[133]	_	_
19-7	2136-2138	in	_	_	_	_
19-8	2139-2148	mediating	_	_	_	_
19-9	2149-2154	rapid	event[134]	new[134]	coref	30-17[221_134]
19-10	2155-2163	response	event[134]	new[134]	_	_
19-11	2164-2166	of	event[134]	new[134]	_	_
19-12	2167-2176	platelets	event[134]|substance	new[134]|new	ana	20-1
19-13	2177-2179	to	event[134]	new[134]	_	_
19-14	2180-2188	vascular	event[134]|event[136]	new[134]|new[136]	coref	25-2[183_136]
19-15	2189-2195	injury	event[134]|event[136]	new[134]|new[136]	_	_
19-16	2196-2197	.	_	_	_	_

#Text=They transmit activation signals from several various platelet receptors .
20-1	2198-2202	They	substance	giv	coref	21-42[156_0]
20-2	2203-2211	transmit	_	_	_	_
20-3	2212-2222	activation	event|abstract[139]	giv|new[139]	coref	21-22[148_0]
20-4	2223-2230	signals	abstract[139]	new[139]	_	_
20-5	2231-2235	from	abstract[139]	new[139]	_	_
20-6	2236-2243	several	abstract[139]|substance[141]	new[139]|new[141]	_	_
20-7	2244-2251	various	abstract[139]|substance[141]	new[139]|new[141]	_	_
20-8	2252-2260	platelet	abstract[139]|object|substance[141]	new[139]|giv|new[141]	coref	25-17
20-9	2261-2270	receptors	abstract[139]|substance[141]	new[139]|new[141]	_	_
20-10	2271-2272	.	_	_	_	_

#Text=There are numerous members of this group and among the SFKs Lyn , Fyn , and Src have been implicated in activation of the GPVI receptor and the integrin receptor signaling and are frequently studied proteins as they are present in both human and mouse platelets .
21-1	2273-2278	There	_	_	_	_
21-2	2279-2282	are	_	_	_	_
21-3	2283-2291	numerous	person[142]	new[142]	ana	21-38[0_142]
21-4	2292-2299	members	person[142]	new[142]	_	_
21-5	2300-2302	of	person[142]	new[142]	_	_
21-6	2303-2307	this	person[142]|animal[143]	new[142]|new[143]	_	_
21-7	2308-2313	group	person[142]|animal[143]	new[142]|new[143]	_	_
21-8	2314-2317	and	_	_	_	_
21-9	2318-2323	among	_	_	_	_
21-10	2324-2327	the	abstract[144]	giv[144]	coref	24-5[169_144]
21-11	2328-2332	SFKs	abstract[144]	giv[144]	_	_
21-12	2333-2336	Lyn	person	new	coref	24-11
21-13	2337-2338	,	_	_	_	_
21-14	2339-2342	Fyn	abstract	new	coref	24-13
21-15	2343-2344	,	_	_	_	_
21-16	2345-2348	and	_	_	_	_
21-17	2349-2352	Src	abstract	new	coref	24-16
21-18	2353-2357	have	_	_	_	_
21-19	2358-2362	been	_	_	_	_
21-20	2363-2373	implicated	_	_	_	_
21-21	2374-2376	in	_	_	_	_
21-22	2377-2387	activation	event[148]	giv[148]	_	_
21-23	2388-2390	of	event[148]	giv[148]	_	_
21-24	2391-2394	the	event[148]|abstract[150]	giv[148]|new[150]	coref	21-29[152_150]
21-25	2395-2399	GPVI	event[148]|abstract|abstract[150]	giv[148]|new|new[150]	_	_
21-26	2400-2408	receptor	event[148]|abstract[150]	giv[148]|new[150]	_	_
21-27	2409-2412	and	event[148]	giv[148]	_	_
21-28	2413-2416	the	event[148]|abstract[153]	giv[148]|giv[153]	_	_
21-29	2417-2425	integrin	event[148]|person|abstract[152]|abstract[153]	giv[148]|new|giv[152]|giv[153]	_	_
21-30	2426-2434	receptor	event[148]|abstract[152]|abstract[153]	giv[148]|giv[152]|giv[153]	_	_
21-31	2435-2444	signaling	event[148]|abstract[153]	giv[148]|giv[153]	_	_
21-32	2445-2448	and	_	_	_	_
21-33	2449-2452	are	_	_	_	_
21-34	2453-2463	frequently	_	_	_	_
21-35	2464-2471	studied	_	_	_	_
21-36	2472-2480	proteins	substance	new	_	_
21-37	2481-2483	as	_	_	_	_
21-38	2484-2488	they	person	giv	_	_
21-39	2489-2492	are	_	_	_	_
21-40	2493-2500	present	_	_	_	_
21-41	2501-2503	in	_	_	_	_
21-42	2504-2508	both	substance[156]	giv[156]	coref	25-12[0_156]
21-43	2509-2514	human	substance[156]	giv[156]	_	_
21-44	2515-2518	and	substance[156]	giv[156]	_	_
21-45	2519-2524	mouse	substance[156]	giv[156]	_	_
21-46	2525-2534	platelets	substance[156]	giv[156]	_	_
21-47	2535-2536	.	_	_	_	_

#Text=TKIs have a different off-target multikinase inhibitory effect .
22-1	2537-2541	TKIs	abstract	giv	_	_
22-2	2542-2546	have	_	_	_	_
22-3	2547-2548	a	abstract[160]	giv[160]	coref	31-14[233_160]
22-4	2549-2558	different	abstract[160]	giv[160]	_	_
22-5	2559-2569	off-target	abstract[160]	giv[160]	_	_
22-6	2570-2581	multikinase	abstract|abstract[160]	giv|giv[160]	_	_
22-7	2582-2592	inhibitory	abstract|abstract[160]	giv|giv[160]	_	_
22-8	2593-2599	effect	abstract[160]	giv[160]	_	_
22-9	2600-2601	.	_	_	_	_

#Text=Comprehensive drug-protein interaction profiles were described to predict the potential side effects of BCR-ABL TKIs .
23-1	2602-2615	Comprehensive	abstract[162]	new[162]	_	_
23-2	2616-2628	drug-protein	abstract[161]|abstract[162]	new[161]|new[162]	_	_
23-3	2629-2640	interaction	abstract[161]|abstract[162]	new[161]|new[162]	_	_
23-4	2641-2649	profiles	abstract[162]	new[162]	_	_
23-5	2650-2654	were	_	_	_	_
23-6	2655-2664	described	_	_	_	_
23-7	2665-2667	to	_	_	_	_
23-8	2668-2675	predict	_	_	_	_
23-9	2676-2679	the	abstract[164]	giv[164]	_	_
23-10	2680-2689	potential	abstract[164]	giv[164]	_	_
23-11	2690-2694	side	abstract|abstract[164]	new|giv[164]	_	_
23-12	2695-2702	effects	abstract[164]	giv[164]	_	_
23-13	2703-2705	of	abstract[164]	giv[164]	_	_
23-14	2706-2713	BCR-ABL	abstract[164]|abstract|abstract[166]	giv[164]|giv|giv[166]	ana	24-1[0_166]
23-15	2714-2718	TKIs	abstract[164]|abstract[166]	giv[164]|giv[166]	_	_
23-16	2719-2720	.	_	_	_	_

#Text=It was found that the most prominent dasatinib-targeted SFKs are Lyn , Fyn , and Src , kinases and their negative regulator C-terminal Src kinase ( Csk ) , but nilotinib does not bind to these kinases .
24-1	2721-2723	It	abstract	giv	_	_
24-2	2724-2727	was	_	_	_	_
24-3	2728-2733	found	_	_	_	_
24-4	2734-2738	that	_	_	_	_
24-5	2739-2742	the	abstract[169]	giv[169]	coref	24-11[173_169]
24-6	2743-2747	most	abstract[169]	giv[169]	_	_
24-7	2748-2757	prominent	abstract[169]	giv[169]	_	_
24-8	2758-2776	dasatinib-targeted	abstract|abstract[169]	new|giv[169]	_	_
24-9	2777-2781	SFKs	abstract[169]	giv[169]	_	_
24-10	2782-2785	are	_	_	_	_
24-11	2786-2789	Lyn	person|abstract[173]|abstract[174]	giv|giv[173]|giv[174]	coref|ana	24-11[174_173]|24-20[0_174]
24-12	2790-2791	,	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
24-13	2792-2795	Fyn	abstract|abstract[173]|abstract[174]	giv|giv[173]|giv[174]	_	_
24-14	2796-2797	,	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
24-15	2798-2801	and	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
24-16	2802-2805	Src	abstract|abstract[173]|abstract[174]	giv|giv[173]|giv[174]	coref	24-24
24-17	2806-2807	,	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
24-18	2808-2815	kinases	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
24-19	2816-2819	and	abstract[174]	giv[174]	_	_
24-20	2820-2825	their	abstract[174]|abstract|substance[176]|abstract[179]	giv[174]|giv|new[176]|giv[179]	appos|coref	24-27[0_179]|24-36[182_0]
24-21	2826-2834	negative	abstract[174]|substance[176]|abstract[179]	giv[174]|new[176]|giv[179]	_	_
24-22	2835-2844	regulator	abstract[174]|substance[176]|abstract[179]	giv[174]|new[176]|giv[179]	_	_
24-23	2845-2855	C-terminal	abstract[174]|place|abstract[179]	giv[174]|new|giv[179]	_	_
24-24	2856-2859	Src	abstract[174]|abstract|abstract[179]	giv[174]|giv|giv[179]	_	_
24-25	2860-2866	kinase	abstract[174]|abstract[179]	giv[174]|giv[179]	_	_
24-26	2867-2868	(	_	_	_	_
24-27	2869-2872	Csk	abstract	giv	_	_
24-28	2873-2874	)	_	_	_	_
24-29	2875-2876	,	_	_	_	_
24-30	2877-2880	but	_	_	_	_
24-31	2881-2890	nilotinib	substance	giv	ana	25-4
24-32	2891-2895	does	_	_	_	_
24-33	2896-2899	not	_	_	_	_
24-34	2900-2904	bind	event	new	coref	27-6[197_0]
24-35	2905-2907	to	_	_	_	_
24-36	2908-2913	these	abstract[182]	giv[182]	_	_
24-37	2914-2921	kinases	abstract[182]	giv[182]	_	_
24-38	2922-2923	.	_	_	_	_

#Text=During vascular injury it is primarily the subendothelial collagen that activates platelets and result in subsequent platelet aggregation .
25-1	2924-2930	During	_	_	_	_
25-2	2931-2939	vascular	event[183]	giv[183]	_	_
25-3	2940-2946	injury	event[183]	giv[183]	_	_
25-4	2947-2949	it	substance	giv	coref	25-6[185_0]
25-5	2950-2952	is	_	_	_	_
25-6	2953-2962	primarily	substance[185]	giv[185]	_	_
25-7	2963-2966	the	substance[185]	giv[185]	_	_
25-8	2967-2981	subendothelial	substance[185]	giv[185]	_	_
25-9	2982-2990	collagen	substance[185]	giv[185]	_	_
25-10	2991-2995	that	substance[185]	giv[185]	_	_
25-11	2996-3005	activates	substance[185]	giv[185]	_	_
25-12	3006-3015	platelets	substance[185]|substance	giv[185]|giv	coref	26-4[190_0]
25-13	3016-3019	and	substance[185]	giv[185]	_	_
25-14	3020-3026	result	substance[185]	giv[185]	_	_
25-15	3027-3029	in	_	_	_	_
25-16	3030-3040	subsequent	abstract[188]	giv[188]	_	_
25-17	3041-3049	platelet	object|abstract[188]	giv|giv[188]	coref	29-10
25-18	3050-3061	aggregation	abstract[188]	giv[188]	_	_
25-19	3062-3063	.	_	_	_	_

#Text=A population of the collagen-adhered platelets responds by surface exposure of the procoagulant phosphatidylserine ( PS ) .
26-1	3064-3065	A	animal[189]	new[189]	_	_
26-2	3066-3076	population	animal[189]	new[189]	_	_
26-3	3077-3079	of	animal[189]	new[189]	_	_
26-4	3080-3083	the	animal[189]|substance[190]	new[189]|giv[190]	coref	28-4[0_190]
26-5	3084-3100	collagen-adhered	animal[189]|substance[190]	new[189]|giv[190]	_	_
26-6	3101-3110	platelets	animal[189]|substance[190]	new[189]|giv[190]	_	_
26-7	3111-3119	responds	_	_	_	_
26-8	3120-3122	by	_	_	_	_
26-9	3123-3130	surface	place|event[192]	new|new[192]	coref	27-2
26-10	3131-3139	exposure	event[192]	new[192]	_	_
26-11	3140-3142	of	event[192]	new[192]	_	_
26-12	3143-3146	the	event[192]|substance[193]	new[192]|new[193]	_	_
26-13	3147-3159	procoagulant	event[192]|substance[193]	new[192]|new[193]	_	_
26-14	3160-3178	phosphatidylserine	event[192]|substance[193]	new[192]|new[193]	_	_
26-15	3179-3180	(	_	_	_	_
26-16	3181-3183	PS	abstract	new	coref	27-1[196_0]
26-17	3184-3185	)	_	_	_	_
26-18	3186-3187	.	_	_	_	_

#Text=This surface expressed PS facilitates the binding of coagulation factors and by this promotes thrombin generation .
27-1	3188-3192	This	abstract[196]	giv[196]	_	_
27-2	3193-3200	surface	place|abstract[196]	giv|giv[196]	_	_
27-3	3201-3210	expressed	abstract[196]	giv[196]	_	_
27-4	3211-3213	PS	abstract[196]	giv[196]	_	_
27-5	3214-3225	facilitates	_	_	_	_
27-6	3226-3229	the	event[197]	new[197]	_	_
27-7	3230-3237	binding	event[197]	new[197]	_	_
27-8	3238-3240	of	event[197]	new[197]	_	_
27-9	3241-3252	coagulation	event[197]|abstract|abstract[199]	new[197]|new|new[199]	coref	29-14[213_0]
27-10	3253-3260	factors	event[197]|abstract[199]	new[197]|new[199]	_	_
27-11	3261-3264	and	_	_	_	_
27-12	3265-3267	by	_	_	_	_
27-13	3268-3272	this	_	_	_	_
27-14	3273-3281	promotes	_	_	_	_
27-15	3282-3290	thrombin	place|abstract[201]	new|giv[201]	_	_
27-16	3291-3301	generation	abstract[201]	giv[201]	_	_
27-17	3302-3303	.	_	_	_	_

#Text=In addition , platelets participate in fibrin formation and regulate the process of clot retraction .
28-1	3304-3306	In	_	_	_	_
28-2	3307-3315	addition	_	_	_	_
28-3	3316-3317	,	_	_	_	_
28-4	3318-3327	platelets	substance	giv	coref	30-21[223_0]
28-5	3328-3339	participate	_	_	_	_
28-6	3340-3342	in	_	_	_	_
28-7	3343-3349	fibrin	person|event[204]	new|new[204]	_	_
28-8	3350-3359	formation	event[204]	new[204]	_	_
28-9	3360-3363	and	_	_	_	_
28-10	3364-3372	regulate	_	_	_	_
28-11	3373-3376	the	event[205]	new[205]	_	_
28-12	3377-3384	process	event[205]	new[205]	_	_
28-13	3385-3387	of	event[205]	new[205]	_	_
28-14	3388-3392	clot	event[205]|object|event[207]	new[205]|new|new[207]	coref|coref	31-24|31-24[238_207]
28-15	3393-3403	retraction	event[205]|event[207]	new[205]|new[207]	_	_
28-16	3404-3405	.	_	_	_	_

#Text=We intended to investigate whether dasatinib also affects the platelet procoagulant activity and thereby coagulation .
29-1	3406-3408	We	person	giv	ana	30-5
29-2	3409-3417	intended	_	_	_	_
29-3	3418-3420	to	_	_	_	_
29-4	3421-3432	investigate	_	_	_	_
29-5	3433-3440	whether	_	_	_	_
29-6	3441-3450	dasatinib	substance	giv	coref	30-15
29-7	3451-3455	also	_	_	_	_
29-8	3456-3463	affects	_	_	_	_
29-9	3464-3467	the	abstract[212]	new[212]	coref	31-19[236_212]
29-10	3468-3476	platelet	object|abstract[212]	giv|new[212]	coref	30-17
29-11	3477-3489	procoagulant	person|abstract[212]	new|new[212]	coref	30-18
29-12	3490-3498	activity	abstract[212]	new[212]	_	_
29-13	3499-3502	and	_	_	_	_
29-14	3503-3510	thereby	abstract[213]	giv[213]	_	_
29-15	3511-3522	coagulation	abstract[213]	giv[213]	_	_
29-16	3523-3524	.	_	_	_	_

#Text=For this reason , we examined the in vitro and ex vivo effects of dasatinib on platelet procoagulant response in dasatinib treated platelets of healthy volunteers and in samples derived from CML patients on dasatinib therapy .
30-1	3525-3528	For	_	_	_	_
30-2	3529-3533	this	abstract[214]	new[214]	_	_
30-3	3534-3540	reason	abstract[214]	new[214]	_	_
30-4	3541-3542	,	_	_	_	_
30-5	3543-3545	we	person	giv	ana	31-1
30-6	3546-3554	examined	_	_	_	_
30-7	3555-3558	the	abstract[217]	new[217]	_	_
30-8	3559-3561	in	abstract[217]	new[217]	_	_
30-9	3562-3567	vitro	abstract|abstract[217]	giv|new[217]	_	_
30-10	3568-3571	and	abstract[217]	new[217]	_	_
30-11	3572-3574	ex	abstract[217]	new[217]	_	_
30-12	3575-3579	vivo	abstract[217]	new[217]	_	_
30-13	3580-3587	effects	abstract[217]	new[217]	_	_
30-14	3588-3590	of	abstract[217]	new[217]	_	_
30-15	3591-3600	dasatinib	abstract[217]|substance	new[217]|giv	coref	30-21
30-16	3601-3603	on	abstract[217]	new[217]	_	_
30-17	3604-3612	platelet	abstract[217]|object|event[221]	new[217]|giv|giv[221]	coref	31-19
30-18	3613-3625	procoagulant	abstract[217]|person|event[221]	new[217]|giv|giv[221]	coref	31-20
30-19	3626-3634	response	abstract[217]|event[221]	new[217]|giv[221]	_	_
30-20	3635-3637	in	abstract[217]|event[221]	new[217]|giv[221]	_	_
30-21	3638-3647	dasatinib	abstract[217]|event[221]|substance|substance[223]	new[217]|giv[221]|giv|giv[223]	coref|coref	30-35|31-34[240_223]
30-22	3648-3655	treated	abstract[217]|event[221]|substance[223]	new[217]|giv[221]|giv[223]	_	_
30-23	3656-3665	platelets	abstract[217]|event[221]|substance[223]	new[217]|giv[221]|giv[223]	_	_
30-24	3666-3668	of	abstract[217]|event[221]|substance[223]	new[217]|giv[221]|giv[223]	_	_
30-25	3669-3676	healthy	abstract[217]|event[221]|substance[223]|animal[224]	new[217]|giv[221]|giv[223]|new[224]	_	_
30-26	3677-3687	volunteers	abstract[217]|event[221]|substance[223]|animal[224]	new[217]|giv[221]|giv[223]|new[224]	_	_
30-27	3688-3691	and	_	_	_	_
30-28	3692-3694	in	_	_	_	_
30-29	3695-3702	samples	object[225]	new[225]	_	_
30-30	3703-3710	derived	object[225]	new[225]	_	_
30-31	3711-3715	from	object[225]	new[225]	_	_
30-32	3716-3719	CML	object[225]|abstract|person[227]	new[225]|giv|new[227]	_	_
30-33	3720-3728	patients	object[225]|person[227]	new[225]|new[227]	_	_
30-34	3729-3731	on	object[225]|person[227]	new[225]|new[227]	_	_
30-35	3732-3741	dasatinib	object[225]|person[227]|substance|abstract[229]	new[225]|new[227]|giv|new[229]	_	_
30-36	3742-3749	therapy	object[225]|person[227]|abstract[229]	new[225]|new[227]|new[229]	_	_
30-37	3750-3751	.	_	_	_	_

#Text=We found that at therapeutic concentration dasatainib , but not nilotinib , has a strong inhibitory effect on platelet procoagulant activity and on clot retraction both in non activated as well as in convulxin activated platelets .
31-1	3752-3754	We	person	giv	_	_
31-2	3755-3760	found	_	_	_	_
31-3	3761-3765	that	_	_	_	_
31-4	3766-3768	at	_	_	_	_
31-5	3769-3780	therapeutic	abstract[231]	new[231]	_	_
31-6	3781-3794	concentration	abstract[231]	new[231]	_	_
31-7	3795-3805	dasatainib	abstract	new	_	_
31-8	3806-3807	,	_	_	_	_
31-9	3808-3811	but	_	_	_	_
31-10	3812-3815	not	_	_	_	_
31-11	3816-3825	nilotinib	_	_	_	_
31-12	3826-3827	,	_	_	_	_
31-13	3828-3831	has	_	_	_	_
31-14	3832-3833	a	abstract[233]	giv[233]	_	_
31-15	3834-3840	strong	abstract[233]	giv[233]	_	_
31-16	3841-3851	inhibitory	abstract[233]	giv[233]	_	_
31-17	3852-3858	effect	abstract[233]	giv[233]	_	_
31-18	3859-3861	on	abstract[233]	giv[233]	_	_
31-19	3862-3870	platelet	abstract[233]|object|abstract[236]	giv[233]|giv|giv[236]	_	_
31-20	3871-3883	procoagulant	abstract[233]|person|abstract[236]	giv[233]|giv|giv[236]	_	_
31-21	3884-3892	activity	abstract[233]|abstract[236]	giv[233]|giv[236]	_	_
31-22	3893-3896	and	_	_	_	_
31-23	3897-3899	on	_	_	_	_
31-24	3900-3904	clot	object|event[238]	giv|giv[238]	_	_
31-25	3905-3915	retraction	event[238]	giv[238]	_	_
31-26	3916-3920	both	event[238]	giv[238]	_	_
31-27	3921-3923	in	event[238]	giv[238]	_	_
31-28	3924-3927	non	event[238]	giv[238]	_	_
31-29	3928-3937	activated	event[238]	giv[238]	_	_
31-30	3938-3940	as	_	_	_	_
31-31	3941-3945	well	_	_	_	_
31-32	3946-3948	as	_	_	_	_
31-33	3949-3951	in	_	_	_	_
31-34	3952-3961	convulxin	person|substance[240]	new|giv[240]	_	_
31-35	3962-3971	activated	substance[240]	giv[240]	_	_
31-36	3972-3981	platelets	substance[240]	giv[240]	_	_
31-37	3982-3983	.	_	_	_	_
